Elevated Financial Group LLC Buys New Shares in Eli Lilly and Company $LLY

Elevated Financial Group LLC bought a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the fourth quarter, Holdings Channel reports. The institutional investor bought 1,180 shares of the company’s stock, valued at approximately $1,269,000.

A number of other institutional investors also recently modified their holdings of the stock. Dumont & Blake Investment Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at $203,000. Simon Quick Advisors LLC lifted its position in shares of Eli Lilly and Company by 46.3% during the 4th quarter. Simon Quick Advisors LLC now owns 7,017 shares of the company’s stock valued at $7,541,000 after acquiring an additional 2,221 shares during the period. ST Germain D J Co. Inc. lifted its position in shares of Eli Lilly and Company by 3.4% during the 4th quarter. ST Germain D J Co. Inc. now owns 1,756 shares of the company’s stock valued at $1,887,000 after acquiring an additional 57 shares during the period. LCM Capital Management Inc acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at $224,000. Finally, High Point Wealth Management LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at $59,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $851.65 on Thursday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The firm has a market cap of $804.65 billion, a price-to-earnings ratio of 37.11, a PEG ratio of 1.03 and a beta of 0.51. The company has a fifty day moving average price of $948.77 and a 200-day moving average price of $985.31.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same quarter in the prior year, the business posted $5.32 EPS. The business’s revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 33.9 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on LLY. Loop Capital set a $1,200.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, February 10th. JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Guggenheim boosted their price target on shares of Eli Lilly and Company from $1,163.00 to $1,183.00 and gave the company a “buy” rating in a research note on Tuesday, April 21st. Weiss Ratings restated a “buy (b)” rating on shares of Eli Lilly and Company in a research note on Friday, March 27th. Finally, CICC Research boosted their price target on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,216.52.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Large AI gene?editing partnership with Profluent (up to $2.25B) broadens Lilly’s digital biology and next?generation genetic medicine pipeline, a long?term growth and valuation positive. Read More.
• Positive Sentiment: Acquisition of Ajax Therapeutics (up to $2.3B) adds a JAK2 myelofibrosis program and deepens oncology exposure — complementary to recent M&A and supports analyst bullishness. Read More.
• Positive Sentiment: Analyst support and price?target moves (e.g., Guggenheim raise) reflect confidence that acquisitions plus pipeline execution justify upside vs. the pullback. This can underpin buying interest if Q1 execution meets expectations. Read More.
• Neutral Sentiment: Wall Street forecasts strong Q1 revenue growth (~36–37%) and investors expect pipeline commentary; earnings results and management commentary will be the immediate catalyst for intraday moves. Read More.
• Neutral Sentiment: Options and trader models imply sizable post?earnings volatility — the report could drive a sharp move either way, so risk around the print is elevated. Read More.
• Negative Sentiment: Early launch data show Foundayo prescriptions lagging a Novo rival and social chatter flags a slow oral GLP?1 rollout; weaker uptake puts short?term pressure on growth expectations for obesity franchise. Read More.
• Negative Sentiment: Canada approved cheaper generic weight?loss drugs, highlighting accelerating competitive and pricing risks in the GLP?1 market that could weigh on sales mix and margins over time. Read More.
• Negative Sentiment: Notable insider selling activity and some fund/portfolio churn reported recently; heavy sales can be perceived negatively by sentiment?driven investors ahead of the quarter. Read More.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.